HIV AIDS medical therapy: Difference between revisions
Line 45: | Line 45: | ||
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''' | ▸ '''Recommended Regimen''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 51: | Line 51: | ||
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''' | ▸ '''Alternative Regimen''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 57: | Line 57: | ||
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''' | ▸ ''' Regimen''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 65: | Line 65: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Recommended Regimen}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''NNRTI-Based Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''NNRTI-Based Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Efavirenz/Tenofovir/Emtricitabine''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Efavirenz/Tenofovir/Emtricitabine<sup>†</sup>''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''PI-Based Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''PI-Based Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Atazanavir/Ritonavir(low dose)''' <br> PLUS <br> ▸ '''Tenofovir/Emtricitabine''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Atazanavir/Ritonavir(low dose)''' <br> PLUS <br> ▸ '''Tenofovir/Emtricitabine<sup>†</sup>''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Darunavir/Ritonavir(low dose)''' br> PLUS <br> ▸ '''Tenofovir/Emtricitabine''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Darunavir/Ritonavir(low dose)''' <br> PLUS <br> ▸ '''Tenofovir/Emtricitabine<sup>†</sup>''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''INSTI-Based Regimen''''' | ||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Dolutegravir ''' <br> PLUS <br> ▸ '''Abacavir/Lamivudine<sup>†</sup> <small>(only for HLA-B*5701 negative patients)</small>''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Dolutegravir ''' <br> PLUS <br> ▸ '''Tenofovir/Emtricitabine<sup>†</sup>''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''Elvitegravir ''' <br> PLUS <br> ▸ ''' ''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small><sup>†</sup>Emtricitabine may be substituted for lamivudine or vice versa<br> <sup>‡</sup></small> | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left | |||
|} | |} | ||
|} | |} |
Revision as of 14:41, 1 October 2014
AIDS Microchapters |
Diagnosis |
Treatment |
Case Studies |
HIV AIDS medical therapy On the Web |
American Roentgen Ray Society Images of HIV AIDS medical therapy |
Risk calculators and risk factors for HIV AIDS medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The primary goal of antiretroviral therapy (ART) is to reduce HIV-associated morbidity and mortality. This goal is best accomplished by using effective ART to maximally inhibit HIV replication, as defined by achieving and maintaining plasma HIV RNA (viral load) below levels detectable by commercially available assays. Durable viral suppression improves immune function and quality of life, lowers the risk of both AIDS-defining and non-AIDS-defining complications, and prolongs life. Based on emerging evidence, additional benefits of ART include a reduction in HIV-associated inflammation and possibly its associated complications.
Medical Therapy
Anti-HIV Medication
Anti-HIV medications (also called antiretrovirals) are grouped into six drug classes according to their mechanism of action. The six classes are as follows:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs).
- Nucleoside reverse transcriptase inhibitors (NRTIs).
- Protease inhibitors (PIs).
- Fusion inhibitors.
- CCR5 antagonists.
- Integrase inhibitors.
Multidrug regimen has proved to be very beneficial because of reduction in progression to AIDS, opportunistic infections, rate of hospitalizations and deaths. [1]
Goals of Therapy
DHHS ART Guidelines present the following goals for therapy:
- Durable suppression of HIV viral load ( to <50 cells/mL ).
- Restoration of normal CD4 cell count.
- Prevention of transmission of the disease.
- Prevention of building of drug resistance.
- Improvement in quality of life of the patient.
Uncontrolled viremia causes inflammation and immune activation, which has an overall effect on cardiovascular, renal and hepatic systems. Controlling viremia also controls these effects.
Indications
Anti Retroviral Therapy (ART)
▸ Click on the following categories to expand treatment regimens.
Anti-retroviral Regimens ▸ Recommended Regimen ▸ Alternative Regimen ▸ Regimen |
|
Related Chapters
- HIV Treatment
- Antiretroviral drug
- Antiretroviral therapy in pregnancy
- Immune reconstitution inflammatory syndrome
References
- ↑ Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M (2005). "Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study". Lancet. 366 (9483): 378–84. doi:10.1016/S0140-6736(05)67022-5. PMID 16054937. Retrieved 2012-02-15.